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Abstract
Background: Breast cancer is the leading cause of cancer mortality among women in Malaysia. Delayed diagnosis
is preventable and has major effects on patients’ prognosis and survival. The objectives of our study were to
identify the magnitude of delayed diagnosis and its associated factors in women with breast cancer in Malaysia.
Methods: This study had a cross-sectional design. Respondents had histologically confirmed breast cancer and
were registered at five medical centres between 2005 and 2007. All breast cancer patients who attended hospital
clinics at the East Coast were included. Patients at Kuala Lumpur hospitals were selected by systematic sampling.
A standardised questionnaire was developed to interview respondents. We measured the time from the first
recognition of symptoms to the first general practitioners’ consultation and to the histological diagnosis of breast
cancer. Diagnosis delay was defined when there was more than 6 months from the recognition of symptoms to
the histological diagnosis. Multiple logistic regression was used for analysis.
Results: In total, 328 respondents were included. The mean (standard deviation) age was 47.9 (9.4) years. Most
respondents were of Malay ethnicity, were married housewives with a median family income of RM1500 a month. Most
respondents had ductal carcinoma (89.3%) and the stage distribution was as follows: 5.2% stage I, 38.7% stage II, 44.8%
stage III and 11.3% stage IV. The median time to consultation was 2 months and the median time to diagnosis was
5.5 months. The frequency of diagnosis delay of more than 3 months was 72.6% and delay of more than 6 months
occurred in 45.5% of the cases. The factors associated with diagnosis delay included the use of alternative therapy
(odds ratio (OR) 1.77; 95% confidence interval (CI): 1.06, 2.94), breast ulcer (OR 5.71; 95% CI: 1.59, 20.47), palpable axillary
lymph nodes (OR 2.19; 95% CI: 1.23, 3.90), false-negative diagnostic test (OR 5.32; 95% CI: 2.32, 12.21), non-cancer
interpretation (OR 1.68; 95% CI: 1.01, 2.78) and negative attitude toward treatment (OR 2.09; 95% CI: 1.15, 3.82).
Conclusions: Delays in consultation and diagnosis are serious problems in Malaysia. Diagnosis delay was
influenced by complex interactions between many factors. Breast awareness and education are required to
promote early detection, diagnosis and treatment before the tumours enlarge and metastasis.
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Background
There were 3525 cases of female breast cancer that were
registered in the National Cancer Registry Malaysia in
2006, accounting for 16.5% of all cancer cases registered
that year [1]. The overall age-standardized rate was 39.3
per 100,000 populations [1]. The cancer incidence in
Malaysia is expected to increase because of increasing life
expectancy, better socio-economic status and changes in
lifestyle. Patients with breast cancer in Malaysia com-
monly present with advanced disease. The Kelantan
Cancer Registry reported that 19.0% of patients presented
in stage I, 25.5% in stage II, 20.7% in stage III and 34.9%
in stage IV [2]. It was previously reported that the 5-year
survival rate in Kuala Lumpur was 59.1% [3], whereas
this rate was 25.8% in Kelantan [4].
The delay in the presentation and detection of patients
with breast cancer is partially responsible for the advanced
stage at presentation and low survival rates in Malaysia.
Early detection of cancer is important because delay is pre-
ventable and earlier treatment can lead to improved
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tumour size, increased involvement of the lymph nodes
and organ metastases [5], and negative implications on
cost and choice of treatment. A study in Thailand reported
that patients with stage III disease had a median delay of
presentation of 2 months compared to those in stage IV
(7 months) [6]. In addition to lower survival rates, patients
with delays of 12 weeks or longer had a significantly higher
probability of local cancer spread or distant metastases
compared to those with shorter delays [7].
Studies in developed countries reported that the median
time to consultation was 14-61 days [8-10]. A delay of
more than 3 months prior to physician consultation
occurred in 14-53% of cases [8-11]. Low socio-economic
status, minority ethnicity and young age were associated
with a longer duration of symptoms [12]. Another study
found that patient delay was associated with older age,
lighter symptoms, not informing anyone, a negative atti-
tude toward medical practitioners and fear of treatment
[13]. Failure of medical practitioners to act on clinical
findings and false-negative mammogram and fine needle
aspiration cytology (FNAC) were the main factors for
system delay [14,15]. Lack of knowledge regarding risk
factors, individual own risk and the variability of symp-
toms of breast cancer, was related to patient delay [16].
This study was conducted to identify the magnitude of
the delay in breast cancer diagnosis and the factors asso-
ciated with this delay. To date, most of the research on
this topic has been conducted in developed countries and
among minorities, and very few studies have been con-
ducted in less developed countries. No studies on this sub-
ject in Malaysia have been published. Research on this
topic is important for clinicians to have a better under-
standing of how to manage patients and so that policy
makers can implement strategies and activities to prevent
delay in breast cancer diagnosis.
Methods
This study had a cross-sectional design. The respondents
were women who were diagnosed with primary breast
cancer by histo-pathological examination between 2005
and 2007. We excluded patients with cognitive problems,
recurrent cancer and incomplete medical records. Respon-
dents were from three referral medical centres in the East
Coast of Malaysia and two government hospitals in Kuala
Lumpur. All patients who attended surgical, oncology and
radiotherapy clinics at the East Coast hospitals during our
s t u d yp e r i o dw e r ei n c l u d e d .Systematic sampling was
conducted on every fourth eligible patient at Kuala
Lumpur hospitals.
Face-to-face interviews were conducted using standar-
dized questionnaires. The questionnaire was developed in
t h eM a l a yl a n g u a g eb a s e do ne x p e r td i s c u s s i o n sa n da
literature review. It was pre-tested for face and content
validity and reliability, which were satisfactory (Cronbach’s
Alpha 0.63-0.92). The content included socio-demography,
medical and obstetric history, the date of all the chronolo-
gical events (i.e., first recognition of symptoms, first consul-
tation, referral, first hospital appointment, first meeting
with the surgeon and oncologist, diagnostic tests and when
the results were known) and the use of alternative therapy.
We considered the symptoms’ interpretation process
spanned from the point at which the women started to
notice abnormalities until a diagnosis was made [17]. An
agreement was decided after discussion with the respon-
dents when there were conflicting dates of events. The
respondents were reminded of events in the calendar year,
such as festival celebrations, Independence Day, school
holidays or birth dates, to help them remember important
dates relative to their medical history.
We also included yes-no questions on the interpreta-
tion of symptoms, knowledge about presenting symp-
toms, aetiology and metastatic organs, beliefs about
breast cancer and treatment, fear, denial, barriers,
healthcare services, husband support, attitude on medi-
cal care and treatment, and health care practices. A
‘yes’ response for positive questions was given a score
of one and a ‘no’ response was given a zero. The scor-
ing was reversed for the negative questions. All scores
for each group were totalled and then categorised
using the median of the total score. We also collected
data from the medical records including clinical pre-
sentation, diagnostic tests, histo-pathological reports
and treatment information.
The Psycho-physiological Comparison Theory devel-
oped by Andersen, Cacioppo and Roberts was taken into
consideration when we formulated the operational defini-
tion of delay [18]. Consultation time was the time taken
to visit the first general practitioner after the recognition
of symptoms. The time to diagnosis was measured from
the date of the recognition of symptoms to the date of
final diagnosis based on histo-pathological examination
of FNAC, trucut or excision biopsy. Breast cancer was
staged according to the 6
th edition of Cancer Staging
Manual published by American Cancer Joint Committee
on Cancer [19]. A family history of breast cancer was
defined as having a first-degree relative, i.e. sister, mother
or daughter who had breast cancer. The respondents
were questioned about previous use of oral contracep-
tives, hormone replacement therapy or alternative ther-
apy if these therapies were taken regularly for at least one
month. Complementary alternative therapy was defined
as any therapy using methods and products not included
in conventional modern medicine. Chronic diseases
assessed in this study included hypertension, diabetes,
heart diseases, asthma and other diseases that require
lifelong monitoring. Misdiagnosis occurred when there
was a false-negative mammogram or FNAC.
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Ethical Committee from all the respective institutions,
with the reference numbers: UKM1.5.3.5/244/SPP2,
HKL/98/AM.882, USMKK/PKK/JK EP(M)-191 USM, Bil
(43)HRPZ ll.71/20 Jld.8, HSNZ.KT.100-22/15(27) and
(4)KKM/NIHSEC/08/0804/P07-13. Respondents were
explained about the research and asked for consent
prior the interview. All information was confidential and
individual data had no identification of the respondents.
Statistical analyses
Data were analysed using SPSS for Windows (version
12.0.1, SPSS Inc., Chicago, IL, USA). Continuous data
were summarised as mean (standard deviation (SD)) or
median (interquartile range (IQR)) depending upon the
normality of distribution, whereas categorical data were
presented as frequency (percentage (%)). We divided the
diagnosis time into a binary outcome, i.e., delay and
non-delay, by using a six-month cut-off point. Six
months was chosen instead of three month to allow
balance number of respondents in each category. Multi-
ple logistic regression was used to identify the factors
associated with diagnosis delay. A stepwise backward
selection procedure was used when selecting significant
variables in the model. The interaction terms and multi-
collinearity problem of the final model were checked.
The final model was tested for fitness using the
Hosmer-Lemeshow goodness of fit test. Results were
presented as the crude and adjusted odd ratios (OR),
95% confidence interval (CI) and p value. The p value
<0.05 was considered to indicate statistical significance.
Results
Background of the respondents
In total, 328 respondents were included in the final analy-
sis. Table 1 shows the socio-demographic characteristics
of the respondents. The mean age was 47.9 years (SD 9.4).
The majority of the respondents were Malays, who were
married housewives with at least a high school education
and a median family income of RM1500 a month. Table 2
shows the medical history of the respondents. Only 8.2%
had a family history of breast cancer, 12.2% had previous
benign breast diseases and 31.4% had comorbid chronic
diseases. Twelve percent did not have any children and
30.5% were post-menopausal. Among the 100 post-meno-
pausal women, only 16.0% had ever taken hormone repla-
cement therapy.
Table 3 shows the clinical characteristics of the respon-
dents. Most cases occurred in the right breast (54.0%) and
2.7% had a second breast cancer in the contralateral
breast. The appearance of a lump was the most common
first symptom. Most (97.6%) had a breast lump at diagno-
sis. Less than 9% had at least one symptom of systemic
Table 1 Socio-demographic characteristics of the
respondents
Socio-demography Frequency (%)
N = 328
Mean (SD)
Age at diagnosis (year) 47.9 (9.4)
40 & less 56 (17.1)
>40 272 (82.9)
Ethnicity
Malay 262 (79.9)
Chinese 46 (14.0)
Indian 14 (4.3)
Others 6 (1.8)
Education level
None 39 (11.9)
Primary school 52 (15.9)
Middle school 37 (11.2)
High school 128 (39.0)
Upper high school 13 (4.0)
Diploma 28 (8.5)
Degree 31 (9.5)
Years of education 9.8 (4.6)
Monthly family income (RM) 1500 (2338)*
Occupation
Housewife 180 (54.9)
Government servant 78 (23.8)
Private sector 44 (13.3)
Self-employed 13 (4.0)
Unemployed 13 (4.0)
Marital status
Married 260 (79.3)
Widow 39 (11.8)
Single 18 (5.5)
Divorce 11 (3.4)
*median (IQR), US$1~Ringgit Malaysia (RM) 3.10.
Table 2 Medical history of the respondents
Medical history Frequency (%)
Family history of breast cancer 27 (8.2)
History of benign breast disease 40 (12.2)
Parity status
Nulliparous 40 (12.2)
Parous 288 (87.8)
Co-morbid chronic disease 103 (31.4)
Oral contraceptive pills 123 (37.5)
Menopausal status
Pre 228 (69.5)
Post 100 (30.5)
Hormone replacement therapy (n = 100) 16 (16.0)
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and treatment of the respondents. In total, 12.9% of the
respondents had benign FNAC and 8.8% had false-nega-
tive mammograms. Most respondents had invasive ductal
carcinoma (89.3%). No respondents had carcinoma in situ.
A total of 37.5% of the respondents had grade 3 disease,
44.8% had stage III and 11.3% had stage IV. Furthermore,
48.2% had oestrogen-receptor-positive, 50.3% had proges-
terone-receptor-positive and 34.8% had C-erb B2-positive
tumours. Most underwent mastectomy (73.8%), 19.2% had
breast conserving surgery and 86.3% and 78.4% completed
chemotherapy and radiotherapy, respectively. There were
48 (14.6%) respondents who initially refused treatment
and 15 (4.6%) respondents refused chemotherapy. In total,
140 (42.7%) respondents took alternative therapy and 48
(14.6%) missed at least one appointment without accepta-
ble reasons. Out of 140 respondents who took alternative
therapy, 67.1% drank enchanted water or applied rice flour
locally to the breast lump.
The magnitude of diagnosis delay
The times to consultation and diagnosis showed skewed
distributions to the right. The range of consultation
time was 0-11 years and the median was 2 months.
Approximately 33.2% of respondents had a medical con-
sultation within one month after detecting symptoms
and 43.3% delayed the consultation by more than 3
months. The range of diagnosis time was 0-16 years and
the median was 5.5 months. Figure 1 shows the diagno-
sis time according to time categories. The frequency of
diagnosis delay of more than 3 months was 72.6% and
the frequency of diagnosis delay of more than 6 months
was 45.5%.
Factors associated with diagnosis delay
Variables with p value <0.25 in the univariable logistic
regression were included in the selection of variables in
the multiple logistic regression modelling. The variables
included the following: locality, ethnicity, years of educa-
tion, employment, family income, breastfeeding, use of
alternative therapy, first symptom, first doctor’sa c t i o n ,
self-detection of symptoms, nipple retraction, breast
ulcer, gross breast swelling, fungating mass, peau de
orange, loss of weight, palpable axillary lymph node,
Table 3 Clinical presentations of the respondents
Clinical characteristics Frequency (%)
Location of tumour on right 177 (54.0)
Second breast cancer on contralateral breast 9 (2.7)
First symptom
Breast lump 288 (87.8)
Nipple problems 12 (3.6)
Breast pain 10 (3.1)
Changes of breast shape 9 (2.8)
No symptom 4 (1.2)
Others 5 (1.5)
Symptom/sign during diagnosis (not exclusive)
Breast lump 320 (97.6)
Nipple retraction 63 (19.2)
Pain at breast 47 (14.3)
Peau de orange 36 (11.0)
Breast ulcer 28 (8.5)
Gross swelling 25 (7.6)
Nipple discharge 22 (6.7)
Fungating 19 (5.8)
Breast dimpling 7 (2.1)
Arm oedema 5 (1.5)
Axillary lymph nodes 87 (26.5)
Supraclavicular lymph nodes 14 (4.3)
Systemic symptom/sign during diagnosis (not
exclusive)
Loss of weight 28 (8.5)
Loss of appetite 20 (6.1)
Bony pain 7 (2.1)
Cachexia 4 (1.2)
Cough 2 (0.6)
Bone fracture 1 (0.3)
Short of breath 1 (0.3)
Table 4 Histo-pathological findings and treatment of the
respondents
Frequency (%)
Benign Fine Needle Aspiration Cytology (FNAC)
(n = 241)
31 (12.9)
False-negative mammogram (n = 136) 12 (8.8)
Invasive ductal carcinoma 293 (89.3)
Stage of breast cancer
I 17 (5.2)
II 127 (38.7)
III 147 (44.8)
IV 37 (11.3)
Bloom Richardson Grade
1 55 (16.8)
2 150 (45.7)
3 123 (37.5)
Estrogens receptor
Positive 158 (48.2)
Negative 149 (45.4)
Not known 21 (6.4)
Progesterone receptor
Positive 165 (50.3)
Negative 142 (43.3)
Not known 21 (6.4)
C-erb B2
Positive 114 (34.8)
Negative 141 (43.0)
Not known 73 (22.2)
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nostic test, defaulter, stage of disease, cancer interpreta-
tion, perceived barrier, attitude of medical consultation,
social support and attitude toward treatment. The final
multiple logistic regression analysis model is shown in
table 5. The factors significantly associated with diagno-
sis delay were the use of alternative therapy (OR 1.77;
95% CI: 1.06, 2.94), breast ulcer (OR 5.71; 95% CI: 1.59,
20.47), palpable axillary lymph nodes (OR 2.19; 95% CI:
1.23, 3.90), false-negative diagnostic test (OR 5.32; 95%
CI: 2.32, 12.21), non-cancer interpretation (OR 1.68;
95% CI: 1.01, 2.78) and negative attitude toward treat-
ment (OR 2.09; 95% CI: 1.15, 3.82). The result of the
H o s m e r - L e m e s h o wg o o d n e s so ff i ts h o w e dt h a tt h e
selected model had a good fit.
Discussion
Our study found that consultation and diagnosis delay
among breast cancer patients are very serious problems
in Malaysia. In the present study, the median times
before consulting a medical practitioner and before diag-
nosis were longer [6,8,9,20], and the prevalence of delay
was higher, than in other studies in developed and
developing countries [5,6,9-11].
Our study found that the clinical presentation was
associated with a delay, which is supported by the litera-
ture [21]. Our study also found that patients who pre-
sented with breast ulcer and palpable axillary lymph
nodes had significantly delayed diagnoses. The delay
would eventually cause breast cancer symptoms to wor-
sen. The first symptoms of breast cancer are usually not
debilitating and can be ignored until the occurrence of
new symptoms or worsening of symptoms. Patients with
aggressive types of breast cancer usually had progressive
symptoms in a short time, causing them to have a high
index of cancer suspicion and seek early consultation
and diagnosis. Patients who had a breast lump had ear-
lier consultations than those with nipple discharge [9]
or pain [22] or non-lump symptoms [23].
False-negative FNAC or mammogram contributed to
the delayed diagnosis of breast cancer in our study.
Only 241 (73.5%) of respondents had FNAC and only
51.2% had positive results of breast cancer and 12.9%
reported as benign. The false-negative FNAC rate in our
study was higher than that reported in other studies,
with only 1.0-1.9% [15,24,25]. Most of the errors
occurred during the performance of the FNAC proce-
dure or the interpretation of the pathological report.
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Figure 1 Diagnosis time of 328 respondents with breast
cancer.
Table 5 Factors associated with diagnosis delay of breast cancer in Malaysian women
Associated factors Frequency (%) Crude Odd
Ratio
a
(95% CI)
Adjusted
Odd Ratio
b
(95% CI)
P
value
b
Non-delay
N = 179
Delay
N = 149
Alternative therapy No 122 (68.2) 66 (44.3) 1.00 1.00 0.029
Yes 57 (31.8) 83 (55.7) 1.69 (1.33, 2.1) 1.77 (1.06, 2.94)
Breast ulcer No 176 (98.3) 124 (83.2) 1.00 1.00 0.008
Yes 3 (1.7) 25 (16.8) 2.16 (1.79, 2.60) 5.71 (1.59, 20.47)
Palpable axillary lymph nodes No 148 (82.7) 93 (62.4) 1.00 1.00 0.008
Yes 31 (17.3) 56 (37.6) 1.67 (1.33, 2.08) 2.19 (1.23, 3.90)
False-negative diagnostic test No 169 (94.4) 122 (81.9) 1.00 1.00 <0.001
Yes 10 (5.6) 27 (18.1) 1.74 (1.37, 2.21) 5.32 (2.32, 12.21)
Interpret symptom as cancer Yes 87 (48.6) 56 (37.6) 1.00 1.00 0.044
No 92 (51.4) 93 (62.4) 1.57 (1.01, 2.44) 1.68 (1.01, 2.78)
Attitude toward treatment Positive 151 (84.4) 109 (73.2) 1.00 1.00 0.016
Negative 28 (15.6) 40 (26.8) 1.98 (1.15, 3.40) 2.09 (1.15, 3.82)
aUnivariable logistic regression
bMultiple logistic regression.
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mammogram and 8.8% of those were false negative,
which is a higher rate than the previous study of only
3% [15]. The acceptable false negative rate of mammo-
gram was 10-15% [26]. The failure of mammograms to
detect breast cancer was related to the limitations of the
film screen, poor radiographic technique, exceptional
tumour characteristics and error in interpreting the film
[26]. In Malaysia, mammograms are not used for screen-
ing except for high-risk women who have had previous
breast cancer or a strong family history of breast cancer.
It is not used for screening because of the high cost and
limited expertise in Malaysia. In Malaysia, there are clin-
ical practice guidelines for breast cancer management,
but the use and implementation of the guidelines are
unknown. More widespread implementation of these
g u i d e l i n e sm a yi n c r e a s et h eq u a l i t yo fc a r ef o rb r e a s t
cancer patients and shorten the diagnosis delay.
In our study, 42.7% of the respondents had taken alter-
native therapy, compared to 14.8-73.1% in Europe [27].
Most patients took alternative therapy as a way to avoid
surgery or when they perceived modern medicine would
not cure the disease, when the prognosis was fatal, when
the disease caused suffering or in cases of chronic dis-
ease. Some patients believed that there were no effective
treatments for breast cancer or that traditional medica-
tion is more effective than modern medicine. While
pursuing alternative treatments, most patients experi-
enced worsening symptoms, which led to them even-
tually presenting at a more advanced stage. A systematic
review reported that people practiced complementary
alternative medicine because of its benefits and because
they wanted to be in control of their treatment, had
strong beliefs and used it as the last hope [27]. Some
patients also have less trust in modern medicine because
they had bad previous experiences or felt that the system
was not as friendly as traditional healers or shaman.
Complementary alternative therapy is also easily available
and affordable.
Patients’ interpretation of their symptoms as a sign of
cancer had an important influence on whether they
sought medical help immediately [28]. The evaluation of
breast symptoms is based on the pre-existing knowledge,
experience, self-education and observation of individuals
[18]. Knowledge regarding the variation of symptoms in
breast cancer enables patients to interpret the symptoms
correctly and influences their assessment of symptoms as
well as their decision to seek medical attention [13].
Patients are more inclined to attribute new symptoms
to less serious conditions instead to a life threatening
disease [18]. Patient delay has been reported for patients
who assumed that symptoms were benign [23] and
would disappear without intervention. Perception of the
seriousness of a symptom is dependent upon the first
symptom and how fast the symptom changes and multi-
plies. Most of breast cancer symptoms are mild, not
specific, unclear, confusing, do not require urgent atten-
tion and can be ignored temporarily.
Our study found that a negative perception of breast
cancer treatment prevented patients from receiving early
diagnoses, similar to a study in Nigeria [29]. Negative
information, such as the side-effects of chemotherapy,
led to fear and caused some patients to refuse treat-
ment. Some believed that the effects of chemotherapy
were worse than breast cancer itself. Another negative
perception of breast cancer treatment was related to the
traditional woman’s role in the family of taking care of
children and the husband. Some believed that treatment
would disrupt and burden their family because they
could not perform their usual roles and might even
have to rely on others to care for them. Because the
women could not take care of the family and the hus-
bands usually had difficulty in taking over the roles of
t h ew o m e n ,t h eh u s b a n dm i g h tc h o o s et os e p a r a t eo r
take another wife. Fear of divorce or the husband
remarrying could lead some women to decide not to get
their symptoms diagnosed if they suspected breast can-
cer. Some patients also believed that breast cancer could
n o tb ec u r e d[ 1 7 ] ,s ot h e r ew a sn op o i n to fh a v i n gi t
diagnosed and treated. Diagnosis delay was also related
to a belief that mastectomy causes disfigurement and
disability [28].
The strength of our study lies in the fact that it was
conducted at five large medical centres in Malaysia. One
of the medical centres on the East Coast was the only
centre that offered oncology and radiotherapy services
in that area. The chances of patients receiving treatment
elsewhere were minimal because most patients could
not afford private services. However, a multicenter study
leads to a considerable variation in the management of
breast cancer patients because medical practitioners
from different hospitals have different preferences.
We collected relevant dates based on the detailed
approach described by Andersen, Cacioppo and Roberts
[18]. Dates of events were collected via interviews with
support from the medical records. Previous report sug-
gests that the collection of actual date is more accurate
than asking about the duration of time [30]. Our study
used face-to-face interviews, in contrast to most other
studies that used the existing medical records, postal or
telephone interviews that had low response rates.
Researchers have no control over the data if the medical
records are used. There are variations in the definitions
of variables, many missing data and a limited number of
variables that can be collected when medical records are
used.
There were differences in defining and categorising the
delay. Most studies divided delays into patient and
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point of three months for categorising delay [5,8,9,14,20].
In our study, we use a six-month cut off point for delay
because our respondents experienced longer delay.
There was a selection bias in recruiting respondents
because they were included after the diagnosis of breast
cancer was made. Our study did not include those who
had died before the study was conducted or those who
were lost to follow up. However, it was assumed that
those who died early had an advanced stage of disease
and had longer delay, suggesting that the diagnosis delay
was under-estimated in our study.
Selection bias also occurred because our study was
conducted in hospitals and some patients may not have
presented to the hospital at all, instead preferring alter-
native treatment. A population-based study was not pos-
sible because of logistic problems in enrolling those
patients.
Furthermore, there was information bias in this study.
Our study method relied on the patients’ recall of the
events leading up to their diagnosis. Patients who delayed
consultation and diagnosis needed to remember more
distant events than those who did not delay. We inter-
viewed respondents after the diagnosis was made instead
of after the recognition of symptoms, so some of the vari-
ables could not be measured retrospectively. We also
could not obtain detailed information on the type and
quality of the diagnostic procedures because we were not
involved in the management of the patients and proce-
dural details were not included in the patients’ medical
records.
Conclusions
Our study found that consultation and diagnosis delays
are very serious problems in Malaysia. The factors signifi-
cantly associated with diagnosis delay were the use of
alternative therapy, breast ulcer, palpable axillary lymph
nodes, false-negative diagnostic test, non-cancer interpre-
tation and a negative attitude toward treatment. Diagno-
sis delay was influenced by a complex interaction of
many factors. Breast awareness and education are needed
to reduce breast cancer mortality by promoting early
detection, diagnosis and treatment before the tumour
enlarges and spreads to lymph nodes and metastasis.
Women should be educated that breast cancer does not
always present as a painless lump; it can also present
with pain, dimpling, swelling or nipple discharge. We
advocate self and clinical breast examinations for women
because the practice is still not at an optimum level in
Malaysia [31], even though there are reports in the litera-
ture indicating that breast self examination failed to
reduce breast cancer mortality [32]. The Ministry of
Health and non-governmental organisations need to
increase and widen their coverage and target groups.
Furthermore, clinical practice guidelines for breast cancer
management should incorporate time guidelines for diag-
nosis and treatment.
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